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Purpose of review 
Giardiasis remains a common cause of diarrhea and intestinal enteropathy globally. Here we give an 
overview of clinical treatment studies and discuss potential mechanisms and molecular targets for in 
vitro testing of drug resistance. 
Recent findings 
Giardia is a cause of disease both in diarrheal and non-diarrheal cases. The prevalence of treatment 
refractory giardiasis is increasing.  Recent studies reveal 5-nitroimidazole refractory infection occurs 
in up to 50% of cases. Mechanisms of drug resistance are not known. 
Placebo controlled studies of drug efficacy, taking the self-limiting course of giardiasis into account, 
has not been reported. No randomized controlled trials of treatment of refractory infection have 
been performed the last 25 years. 
Based on the clinical studies reported, combination treatment with a 5-nitroimidazole and a 
benzimidazole is more effective than repeated courses of 5-nitroimidazole or monotherapies in 
refractory cases. Quinacrine is effective in refractory cases, but potentially severe side effects limit its 
use.  
Summary 
A combination of a 5-nitroimidazole and albendazole or mebendazole, and quinacrine monotherapy, 
are rational choices in nitroimidazole refractory infections, but randomized controlled studies are 
needed.   
Further research into more recent clinical isolates is necessary to uncover mechanisms for the 
increase in metronidazole refractory giardiasis observed during the last decade. 
 
Keywords 






Giardiasis is a protozoan infection of the small bowel, frequently responsible for traveler’ diarrhea [1, 
2], and for complications from chronic or repeated infections [3, 4].  
 
The infectious cysts can survive for months in the environment, explaining why the infection is 
closely associated with unsafe water. In low- and middle-income countries (LMIC), the incidence is 
very high and in some areas close to 100% of children have had one or more Giardia infections 
before the age of 2 years [3, 5, 6]. In high-income countries, Giardia is a frequent cause of 
waterborne outbreaks [7], as in Bergen, Norway in 2004 where approximately 2500 people were 
treated for giardiasis [8].   
 
In a non-endemic area, clinical infection in all age groups range from asymptomatic carrier state to 
severe abdominal pain, diarrhea, vomiting, flatulence, malabsorption, anorexia and weight loss, with 
a fraction of patients developing post-infectious irritable bowel disease and chronic fatigue [8-11].  
Histological findings in over 500 cases of giardiasis found normal appearance of the duodenal mucosa 
in the majority of cases; Only a minority of cases revealed duodenal inflammation and mild villous 
shortening on light microscopy [12]. However, in previously unexposed adults, protracted infection 
has been associated with duodenal inflammation [13, 14] and increased risk of post-infectious 
complications [15].  
 
In low-resource settings, Giardia infection is common both in diarrheal and non-diarrheal cases, and 
is associated with chronic diarrhea [16]. It mainly occurs in children, and a serious manifestation is its 
contribution to malnutrition and stunting of growth following early or repeated infections [3, 17-20]. 
Two large multicenter studies of diarrhea etiology in LMIC reported that Giardia was more prevalent 
in controls than in diarrheal cases [21, 22], leading to speculations about a potential negative 
association between Giardia and acute infectious diarrhea. However, after adjusting for 
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metronidazole exposure in diarrhea cases in the MAL-ED study [3], a negative association between 
Giardia and diarrhea was not significant.  
 
A small experimental study among adults challenged with Giardia revealed that establishment of 
infection was dose dependent and shedding was self-limited in 85% of individuals, but 15% of 
individuals developed chronic shedding [23]. The mean duration of infection in spontaneously cured 
cases was almost three weeks. It is rational to treat giardiasis both in endemic and non-endemic 
areas, in order to prevent complications, chronic disease and spread of the infection.  
 
The first line treatment of giardiasis are the 5-nitroimidazoles, but there are reports of high incidence 
of nitroimidazole refractory cases of giardiasis [24, 25]. Although antimicrobial resistance is an 
increasing problem in giardiasis, in vitro susceptibility testing methods to help clinicians guide 
targeted treatment is not available. This review provide an overview of clinical studies of anti-Giardia 
treatment and suggest choice of treatment in refractory cases, and discuss potential mechanisms 
and molecular targets for future in vitro testing of drug resistance. 
 
Treatment of giardiasis 
Until a few decades ago, Giardia lamblia was considered an innocent bystander in the microbial gut 
flora, but after the pathogenicity of the parasite was recognized, different classes of drugs have been 
used [26]. Current therapies, with different availability across countries, include nitroimidazole 
derivatives (metronidazole, tinidazole, secnidazole and ornidazole), benzimidazoles (albendazole, 
mebendazole), nitazoxanide, furazolidone, quinacrine, chloroquine and paromomycin.  
 
Current treatment options 
5 
 
Randomized controlled trials (RCT) of drugs used in first line treatment of giardiasis are listed in Table 
1. Efficacy is evaluated by stool microscopy post-treatment in all the studies. Study designs are 
heterogeneous regarding study population, dose and duration of treatment, time until follow up and 
number of stool samples examined. 
 
5-nitroimidazoles 
5-nitroimidazoles are the most frequently used first line drugs. These drugs become activated after 
entering the parasite, and kills the microorganism by release of reactive, toxic, partially reduced 
intermediates [27]. Tinidazole, secnidazole and ornidazole have long half-lifes, and cure rates above 
90% are reported when single dose (sd) regimens of 1-2 g in adults and 30 mg/kg (secnidazole), 20-40 
mg/kg (ornidazole) and 50 mg/kg (tinidazole) in children, are given (Table 1). These nitroimidazoles 
are better tolerated than metronidazole. Metronidazole has a shorter half-life, and longer courses 
are needed to achieve similar efficacy; 250 mg three times daily (tid) for 7 days or 500 mg tid for 5 
days in adults, and 5-7 mg/kg tid for 5-7 days in children. Reported side effects are gastrointestinal 
discomfort, anorexia, metallic taste, disulphiram-like effect, headache, vertigo, insomnia, irritability, 
neuropathy, seizures, rash, leukopenia, hepatitis and pancreatitis (references in Table 1).  
 
Benzimidazoles 
Albendazole and mebendazole are widely used anti-helminthic drugs, but treatment efficacy in 
giardiasis is variable (Table 1). The benzimidazoles exert their function by binding to, and preventing 
microtubule transport and assembly, and may also induce oxidative stress in the parasite [28]. 
Albendazole 400mg in adults, and 10 mg/kg in children, sd for 5 days, show 83-96% efficacy, while 
shorter duration is less effective. Efficacy for mebendazole vary greatly (14 - 95%), both for sd 
treatment and for dosage 200 mg tid up to 7 days. Benzimidazoles are usually well tolerated; 





The oral aminoglycoside paromomycin is the drug of choice for giardiasis in pregnant women, 
because it is poorly absorbed and has no systemic effect [29]. Paromomycin inhibits the protein 
synthesis in Giardia [30]. Although this is the only anti-Giardia drug considered completely safe 
during early pregnancy, few clinical studies of treatment efficacy has been reported (Table 1). In a 
controlled study from Cuba among 256 children, efficacy was 92% compared to 80% for 
metronidazole [31], while a small case series from 1962 using 15 mg/kg/d for 5 days reported 40% 
efficacy [32].  
 
Acridine 
Quinacrine is an effective anti-Giardia drug (Table 1), although its exact mechanism of action in 
Giardia is not known [33]. Two studies among children treated for 5 days report 100% efficacy. 
However, quinacrine has bothersome and potentially severe side effects. In a study reporting 77% 
efficacy, severe vomiting explained most of the treatment failures in small children [34]. In a study 
from Cuba reporting 84% efficacy, nausea, vomiting, discoloration of skin and headache was 
significantly more common than in the metronidazole group [35].  Yellow discoloration of skin is a 
common but harmless and self-limiting side effect [34-36], while neuropsychiatric disturbances 




Furazolidone has shown high efficacy in studies of first line therapy, although no RCTs are reported 
since 1980s (Table 1). It is a prodrug which release damaging intermediates when its nitro group is 
reduced [40]. The drug is contraindicated in glucose-6-phosphate-dehydrogenase (G6PD) deficiency 





Nitazoxanide is the only available drug for Cryptosporidium, and like metronidazole it is also activated 
by reduction of its nitro group and inhibits metabolic enzymes [41]. In controlled studies of giardiasis, 
it has shown efficacies between 44% and 91% (Table 1). It may cause some gastrointestinal 
discomfort but is usually well tolerated.  
 
Chloroquine 
Chloroquine is effective against non-falciparum malaria and rheumatic disorders. Its mechanism of 
action against giardiasis is not known, but it may limit the trophozoite adherence to the intestinal 
wall. Its effect against Giardia has been investigated in RCT’s in Cuba; in a large study among 
children, efficacy was 86% compared to 91% for tinidazole and 62% for albendazole [42]. Reported 
side effects were bitter taste and gastrointestinal problems, similar to for tinidazole. Chloroquine 
may potentially cause prolonged Q-T time, and hemolytic anemia in G6PD deficiency [43].  
 
Treatment of refractory giardiasis 
Drug trials have usually shown efficacy above 90% for the nitroimidazoles (Table 1), however, 
treatment refractory disease is an increasing problem. In a study from England, nitroimidazole failure 
increased from 15% (n=8/53) in 2008 to 40% (n=35/87) in 2013, and among travelers from India 
treatment failure occurred in as much as 50% [24].  
The association between location of contracting infection and nitroimidazole failure, in four clinical 
studies, is shown in Table 2. As much as 46% failure was reported after metronidazole 500 mg tid for 
5 days in a large cohort from Cuba in 2018 [25]. Although there are few studies and number of cases 
are small, treatment failure among European travelers seemed to be more common after travel to 




A few clinical, mainly small, studies are available providing evidence for treatment efficacy in 
refractory cases (Table 3). Observational studies show that another class of drug, combination 
therapy, or repeated courses with increased dose/duration of the same drug is used with varying 
efficacy.  
Quinacrine is effective in almost all cases, but due to availability problems and potentially severe side 
effects, the drug is normally preferred only when other treatment options fail. Both quinacrine in 
combination with a 5-nitroimidazole for up to three weeks, and quinacrine monotherapy for as short 
as three days, were effective in reported studies (Table 3).  
Combination of drugs from different classes also seem to be an effective second line option. 
Albendazole in combination with metronidazole was effective in 90% in a small RCT in Italy [44], and 
79% effective in a prospective treatment ladder study in Norway [45]. The combination of 
secnidazole and mebendazole was effective in 89% in a large treatment ladder study in Cuba, while a 
repeated course of 5-nitroimidazole after initial metronidazole treatment cured only 24% - 27% [25].  
Albendazole monotherapy seem to be less effective, although number of cases reported are small 
(Table 3). 
 
Drug resistance in giardiasis 
Antimicrobial resistance is defined by WHO as “the ability of a microorganism (like bacteria, viruses, 
and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from 
working against it. As a result, standard treatments become ineffective, infections persist and may 
spread to others” [46]. There are no defined molecular resistance mechanisms in Giardia yet, thus the 
term treatment refractory is better suited to describe treatment failure, as there is no doubt that also 
the hosts’ combined immune defenses play a role in eradicating the parasite. 
 
Treatment refractory clinical infections have mostly been observed against the 5-nitroimidazole drug 
metronidazole [24].  To exert its antibiotic function, metronidazole needs to be activated by 
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intracellular reduction of its nitro group, creating hyper-reactive intermediates, disrupting the 
microorganism by excessive oxidative stress [33]. Four enzymes have been identified in the 
metabolism of Giardia that seem capable of activating metronidazole by partial reduction into toxic 
hyper-reactive intermediates; nitroreductase 1 (NR) 1 [47], pyruvate:ferredoxin oxidoreductase 
(PFOR) 1 and 2 [48, 49] and the thiol-cycling associated enzyme thioredoxin reductase (TrxR) [48, 50]. 
This partial reduction only occurs under anaerobic or microaerophilic conditions.  
 
Inducing resistance in vitro, by gradually increasing drug concentrations in growth media of a small 
fraction of Giardia strains that can be cultured, is quite easy. Most research on resistance 
mechanisms have been performed on such laboratory strains, isolated from infected humans 
decades ago [51]. Interestingly the drug resistance seen in laboratory induced strains is reduced or 
lost if the trophozoites pass through a cyst stage [52]. It is unknown how important this non-
transmissible resistance is in clinical practice, but the rapidly increasing resistant infections seen, 
indicates the presence of new heritable traits conferring metronidazole resistance, or the ability to 
rapidly develop it. Typing of metronidazole resistant isolates in two studies show that several 
subgroups of assemblage A and B isolates are represented among resistant strains [53, 54]. 
 
Elucidating mechanisms of drug resistance 
Methods for determining resistance in Giardia is not easily available. Only a small fraction of clinical 
isolates will grow in available liquid culture media, with assemblage A more often being successful 
than assemblage B parasites [55]. Strains will grow at different speeds making measurement of 
growth inhibition in drug dilutions very difficult to standardize, even for the few isolates that are 
culturable [56, 57]. 
Compared to bacteria, identifying genetic markers of resistance in an early eukaryote, binucleate, 
functionally tetraploid organism such as Giardia is challenging. A relatively high degree of genetic 
10 
 
diversity is seen in the metronidazole activating genes [48], both between isolates and in the up to 
four alleles of each gene. This offers Giardia substantial potential for variability to tweak its 
metabolism and for selection of well-adapted variants.  
 
Studies analyzing both genes and gene expression in metronidazole resistant laboratory strains and 
their metronidazole-susceptible ancestor, find a quite broad and variable adaptive response in the 
resistant isotypes [58]. There seem to be both post-transcriptional and post-translational alterations 
[27, 52, 59], and Giardia thereby seem to have several ways it may develop tolerance to 
metronidazole.  
 
A frequent finding in the few existing studies in metronidazole-resistant laboratory strains has been 
downregulation of NR1 [58-60]. One isolate has been shown to harbor a non-sense mutation in 
transcripts of this gene, inferring that it may have substantially lower levels of this metronidazole-
activating enzyme [58]. Results from genetic analysis of the other metronidazole metabolizing 
enzymes have been less consistent, but indicates a role for NR2, PFOR, and TrxR and Flavin 
Mononucleotide-dependent oxidoreductases in resistance against metronidazole [27]. 
 
In a study examining protein expression in Giardia strains made gradually resistant in vitro against 
metronidazole and nitazoxanide, no specific trait or marker was identified [61]. Rather, it seemed 
that each of the three resistant strains had found their own strategy for tolerating high level of the 
drugs.  
 
Thus, we can conclude that despite the carefully designed gene and protein expression studies in 
cultured isolates we still have very limited knowledge regarding the ways Giardia protects itself from 
drugs such as metronidazole. However, laboratory induced resistant strains gathered decades ago 
may be quite different from the metronidazole refractory isolates now circulating. The rapidly 
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increasing resistance reported [24, 25], suggest that there are genetic changes that helps the parasite 
overcome the toxic effects of metronidazole, but further research is needed in clinical isolates.  
 
Conclusion 
Nitroimidazole failure in up to 50% is reported in giardiasis, both among travelers and in high 
endemic countries. Repeated courses of nitroimidazole, and monotherapy with a drug with another 
mode of action, seem to be less effective than combination therapy. A combination of a 5-
nitroimidazole and albendazole or mebendazole, and quinacrine as last option, are rational choices in 
nitroimidazole refractory infections. 
Research in drug resistant Giardia laboratory strains have not yet succeeded in identifying 
mechanisms, or markers, of resistance but show that Giardia strains possess a varied 
armamentarium of adaptations. Further research into more recent clinical isolates seems necessary 
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• Giardiasis is an important cause of diarrhea and malabsorption. 
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• Clinical resistance against 5-nitroimidazoles is an increasing problem. 
• A 5-nitroimidazole in combination with a benzimidazole, and quinacrine monotherapy, are effective 
second and third line treatment options. 
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